Press Release
Press Release
MSD sinks $4bn upfront into ADC pact with Daiichi Sankyo | pharmaphorum
Press Release Daiichi Sankyo and Ranbaxy to leverage synergies in Thailand Tokyo, Japan and Gurgaon, India, January 16, 2013: Da
Daiichi press release found to discredit pharma on safety basis
Press release - Daiichi Sankyo and LYSA-LYSARC-CALYM - Lymphoma Research Experts
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo's ADC DS-1062 | World Pharma Today
Daiichi Sankyo Reports Submission of NDA to MHLW for Valemetostat to Treat T-Cell Leukemia/Lymphoma
Press Release - TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer
Press Release - Daiichi Sankyo Ships “VAXZEVRIATM Intramuscular Injection,” AstraZeneca COVID-19 Vaccine
Press Release - Quizartinib Granted Priority Review in the US for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
Press Release
Press Releases - Media - Daiichi Sankyo
Daiichi Sankyo Abandons 6 Clinical Programs in Q1 Update | BioSpace
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs | Business Wire
Daiichi Sankyo, Inc. on LinkedIn: Press Releases - Daiichi Sankyo US
Daiichi Sankyo, Inc. on LinkedIn: Press Releases - Daiichi Sankyo US
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation | Business Wire
Daiichi Sankyo et Gustave Roussy Concluent un Accord de Collaboration de Recherche pour le Développement des Anticorps Conjugués au DXd, DS-1062 et Patritumab Déruxtécan | Business Wire
AWS Case Study: Daiichi Sankyo Co., Ltd. | AWS
Merck signs $5.5 billion deal with Daiichi for cancer therapy development - The Japan Times
Daiichi Sankyo Joins SCRS Global Impact Partner Program – Society for Clinical Research Sites
Press Release
Daiichi Sankyo will remain dominant in ADC market for oncology treatments: GlobalData - Express Pharma
SIT Laboratorio Farmaceutico a company of DESMA HC Group Acquires LOPRESSOR, ICAZ and MIOREL from Daiichi Sankyo France :: desmahealthcare.com
Daiichi Sankyo and Syneos Health Form Strategic Coalition for Development of Daiichi Sankyo's ADC Oncology Pipeline | World Pharma Today
Press release - Daiichi Sankyo and LYSA-LYSARC-CALYM - Lymphoma Research Experts
